SMYD3 regulates gastric cancer progression and macrophage polarization through EZH2 methylation

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  Google Scholar 

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

Article  Google Scholar 

Zhang JK, Fang LL, Zhang DW, Jin Q, Wu XM, Liu JC, et al. Type D personality in gastric cancer survivors: association with poor quality of life, overall survival, and mental health. J Pain Symptom Manag. 2016;52:81–91.

Article  Google Scholar 

Diniz TP, da Costa WL, Jr., Gomes CC, de Jesus VHF, Felismino TC, Torres SM, et al. Symptomatic recurrence and survival outcomes after curative treatment of gastric cancer: does intensive follow-up evaluation improve survival? Ann Surg Oncol. 2021;29:274–284.

Sindayigaya R, Dogan C, Demtroder CR, Fischer B, Karam E, Buggisch JR, et al. ASO visual abstract: clinical outcome of patients managed with low-dose cisplatin and doxorubicin delivered as pressurized intraperitoneal aerosol chemotherapy for unresectable peritoneal metastases of gastric cancer. Ann Surg Oncol. 2021;29:112–23.

Zhang XY, Zhang PY. Gastric cancer: somatic genetics as a guide to therapy. J Med Genet. 2017;54:305–12.

CAS  Article  Google Scholar 

Huang J, Gou H, Yao J, Yi K, Jin Z, Matsuoka M, et al. The noncanonical role of EZH2 in cancer. Cancer Sci. 2021;112:1376–82.

CAS  Article  Google Scholar 

Gan L, Xu M, Hua R, Tan C, Zhang J, Gong Y, et al. The polycomb group protein EZH2 induces epithelial-mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter. J Hematol Oncol. 2018;11:9.

Article  Google Scholar 

Guo L, Yang TF, Liang SC, Guo JX, Wang Q. Role of EZH2 protein expression in gastric carcinogenesis among Asians: a meta-analysis. Tumour Biol. 2014;35:6649–56.

CAS  Article  Google Scholar 

Wang C, Li X, Zhang J, Ge Z, Chen H, Hu J. EZH2 contributes to 5-FU resistance in gastric cancer by epigenetically suppressing FBXO32 expression. Onco Targets Ther. 2018;11:7853–64.

CAS  Article  Google Scholar 

Nakagawa S, Okabe H, Ouchi M, Tokunaga R, Umezaki N, Higashi T, et al. Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma. HPB (Oxf). 2018;20:939–48.

Article  Google Scholar 

Tsou PS, Campbell P, Amin MA, Coit P, Miller S, Fox DA, et al. Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma. Proc Natl Acad Sci USA. 2019;116:3695–702.

CAS  Article  Google Scholar 

Gollner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein HU, Rohde C, et al. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. Nat Med. 2017;23:69–78.

Article  Google Scholar 

Jarrell DK, Hassell KN, Alshiraihi I, Crans DC, Brown MA. Structural analysis of SMYD3 lysine methyltransferase for the development of competitive and specific enzyme inhibitors. Diseases. 2021;10:4.

Matsui H, Iriyama T, Sayama S, Inaoka N, Suzuki K, Yoshikawa M, et al. Elevated placental histone H3K4 methylation via upregulated histone methyltransferases SETD1A and SMYD3 in preeclampsia and its possible involvement in hypoxia-induced pathophysiological process. Placenta. 2021;115:60–9.

CAS  Article  Google Scholar 

Liu Y, Deng J, Luo X, Pan Y, Zhang L, Zhang R, et al. Overexpression of SMYD3 was associated with increased STAT3 activation in gastric cancer. Med Oncol. 2015;32:404.

Article  Google Scholar 

Bottino C, Peserico A, Simone C, Caretti G. SMYD3: an oncogenic driver targeting epigenetic regulation and signaling pathways. Cancers (Basel). 2020;12:142.

Eich ML, Athar M, Ferguson JE 3rd, Varambally S. EZH2-targeted therapies in cancer: hype or a reality. Cancer Res. 2020;80:5449–58.

Article  Google Scholar 

Zhu L, Zhang C, Xue J, He X, Yin D, Zhu Q, et al. EZH2-mediated epigenetic suppression of lncRNA PCAT18 predicts a poor prognosis and regulates the expression of p16 by interacting with miR-570a-3p in gastric cancer. J Cancer. 2021;12:7069–78.

CAS  Article  Google Scholar 

Ma X, Chen H, Li L, Yang F, Wu C, Tao K. CircGSK3B promotes RORA expression and suppresses gastric cancer progression through the prevention of EZH2 trans-inhibition. J Exp Clin Cancer Res. 2021;40:330.

CAS  Article  Google Scholar 

Kong WQ, Liang JJ, Du J, Ye ZX, Gao P, Liang YL. Long noncoding RNA DLX6-AS1 regulates the growth and aggressiveness of colorectal cancer cells via mediating the miR-26a/EZH2 Axis. Cancer Biother Radiopharm. 2021;36:753–64.

CAS  Article  Google Scholar 

Yuan H, Han Y, Wang X, Li N, Liu Q, Yin Y, et al. SETD2 restricts prostate cancer metastasis by integrating EZH2 and AMPK signaling pathways. Cancer Cell. 2020;38:350–65e7.

CAS  Article  Google Scholar 

Xu J, Wang Z, Lu W, Jiang H, Lu J, Qiu J, et al. EZH2 promotes gastric cancer cells proliferation by repressing p21 expression. Pathol Res Pract. 2019;215:152374.

CAS  Article  Google Scholar 

Hanaki S, Shimada M. Targeting EZH2 as cancer therapy. J Biochem. 2021;170:1–4.

CAS  Article  Google Scholar 

Thienger P, Rubin MA. SETting up for epigenetic regulation of advanced prostate cancer. Cancer Cell. 2020;38:309–11.

CAS  Article  Google Scholar 

Kang SY, Hwang D, Shin S, Park J, Kim M, Rahman MDH, et al. Potential of bioactive food components against gastric cancer: insights into molecular mechanism and therapeutic targets. Cancers (Basel). 2021;13:4502.

Ciraku L, Esquea EM, Reginato MJ O-GlcNAcylation regulation of cellular signaling in cancer. Cell Signal. 2021;13:5365.

Abumustafa W, Zamer BA, Khalil BA, Hamad M, Maghazachi AA, Muhammad JS. Protein arginine N-methyltransferase 5 in colorectal carcinoma: Insights into mechanisms of pathogenesis and therapeutic strategies. Biomed Pharmacother. 2021;145:112368.

Article  Google Scholar 

Lee YH, Kim SJ, Fang X, Song NY, Kim DH, Suh J, et al. JNK-mediated Ser27 phosphorylation and stabilization of SIRT1 promote growth and progression of colon cancer through deacetylation-dependent activation of Snail. Mol Oncol. 2021;16:1555–1571.

Zhang Z, Li X, Yang F, Chen C, Liu P, Ren Y, et al. DHHC9-mediated GLUT1 S-palmitoylation promotes glioblastoma glycolysis and tumorigenesis. Nat Commun. 2021;12:5872.

CAS  Article  Google Scholar 

Guo J, Zheng J, Zhang H, Tong J. RNA m6A methylation regulators in ovarian cancer. Cancer Cell Int. 2021;21:609.

CAS  Article  Google Scholar 

Teng PC, Liang Y, Yarmishyn AA, Hsiao YJ, Lin TY, Lin TW, et al. RNA modifications and epigenetics in modulation of lung cancer and pulmonary diseases. Int J Mol Sci. 2021;22:10592.

Sanese P, Fasano C, Simone C. Playing on the dark side: SMYD3 acts as a cancer genome keeper in gastrointestinal malignancies. Cancers (Basel), 2021;13:4427.

Huang L, Xu AM. SET and MYND domain containing protein 3 in cancer. Am J Transl Res. 2017;9:1–14.

PubMed  PubMed Central  Google Scholar 

Giakountis A, Moulos P, Sarris ME, Hatzis P, Talianidis I. Smyd3-associated regulatory pathways in cancer. Semin Cancer Biol. 2017;42:70–80.

CAS  Article  Google Scholar 

Li Z, Wang D, Chen X, Wang W, Wang P, Hou P, et al. PRMT1-mediated EZH2 methylation promotes breast cancer cell proliferation and tumorigenesis. Cell Death Dis. 2021;12:1080.

CAS  Article  Google Scholar 

Adibfar S, Elveny M, Kashikova HS, Mikhailova MV, Farhangnia P, Vakili-Samiani S, et al. The molecular mechanisms and therapeutic potential of EZH2 in breast cancer. Life Sci. 2021;286:120047.

CAS  Article  Google Scholar 

Park SH, Fong KW, Mong E, Martin MC, Schiltz GE, Yu J. Going beyond Polycomb: EZH2 functions in prostate cancer. Oncogene. 2021;40:5788–98.

CAS  Article  Google Scholar 

Heo KS. Regulation of post-translational modification in breast cancer treatment. BMB Rep. 2019;52:113–8.

CAS  Article  Google Scholar 

Li Z, Li M, Wang D, Hou P, Chen X, Chu S, et al. Post-translational modifications of EZH2 in cancer. Cell Biosci. 2020;10:143.

CAS  Article  Google Scholar 

留言 (0)

沒有登入
gif